TrialCancer medicine2026

Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study.

Bei Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.